Genetic deletion of monoacylglycerol lipase (MAGL) leads to impaired cannabinoid receptor CB1 R signaling and anxiety-like behavior

Endocannabinoids (eCB) are key regulators of excitatory/inhibitory neurotransmission at cannabinoid-1-receptor (CB1R)-expressing axon terminals. The most abundant eCB in the brain, that is 2-arachidonoylglycerol (2-AG), is hydrolyzed by the enzyme monoacylglycerol lipase (MAGL), whose chronic inhibition in the brain was reported to cause CB1R desensitization. We employed the MAGL knock-out mice (MAGL-/-), a genetic model of congenital and sustained elevation of 2-AG levels in the brain, to provide morphological and biochemical evidence for β-arrestin2-mediated CB1R desensitization in brain regions involved in the control of emotional states, that is, the prefrontal cortex (PFC), amygdala, hippocampus and cerebellar cortex. We found a widespread CB1R/β-arrestin2 co-expression in the mPFC, amygdala and hippocampus accompanied by impairment of ERK signaling and elevation of vesicular glutamate transporter (VGluT1) at CB1R-positive excitatory terminals in the mPFC, or vesicular GABA transporter (VGAT) at CB1R-positive inhibitory terminals in the amygdala and hippocampus. The impairment of CB1R signaling in MAGL-/- mice was also accompanied by enhanced excitatory drive in the BLA-mPFC circuit, with subsequent elevation of glutamate release to the mPFC and anxiety-like behavior, as assessed by the marble burying test. Collectively, these data provide evidence for a β-arrestin2-mediated desensitization of CB1R in MAGL-/- mice, with impact on the synaptic plasticity of brain circuits involved in emotional functions. This article is protected by copyright. All rights reserved.